PharmAust (PAA) Stock Overview

PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

PAA Stock Information

Symbol

PAA

Address

5/3 Brodie Hall DriveBentley, WA 6102Australia

Founded

Trading hours

10:00 AM - 4:00 PM AEST

Website

https://www.pharmaust.com

Country

🇦🇺 Australia

Phone Number

61 8 9202 6814

PharmAust (PAA) Price Chart

PharmAust Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.11501095986794035	N/A
Market Cap	$36.92M	N/A
Shares Outstanding	321.01M	1.30%
Employees	0	N/A
Shareholder Equity	3.89M	-50.42%

Valuation	2023	Change
P/E Ratio	-5.96	N/A
P/S Ratio	19.32	N/A
P/B Ratio	9.49	N/A

Growth	2023	Change
Return on Equity	-1.0805	N/A

Earnings	2023	Change
Revenue	$1.91M	N/A
Earnings	-$4.20M	N/A
EPS	-0.0193	N/A
Earnings Yield	-0.1678	N/A
Gross Margin	0.7211	N/A
Operating Margin	-1.31	N/A
Net income margin	-2.20	N/A

Financial Strength	2023	Change
Total Assets	$4.15M	N/A
Total Debt	$709.66K	N/A
Cash on Hand	$1.83M	N/A
Debt to Equity	0.3899	102.37%
Cash to Debt	$2.58	47.91%
Current Ratio	$2.24	-29.93%